TY  - BOOK
AU  - Enas Nagi Gaafar
AU  - Amr Abdalla Salem , 
AU  - Ebraheem Abdalrahman Ebraheem , 
AU  - Hossam Eldeen Ahmed Abdelmonem , 
TI  - Outcome of pediatric patients with rhabdomyosarcoma at National Cancer Institute, Egypt / 
PY  - 2019///
CY  - Cairo : 
PB  - Enas Nagi Gaafar , 
KW  - Combined modality therapy
KW  - IRS risk grouping
KW  - Rhabdomyosarcoma in pediatric patients
N1  - Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology; Issued also as CD
N2  - Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in infants and children. It is the third most common solid tumor in children after neuroblastoma and Wilms tumor, making up 10-15% of all solid pediatric tumors. RMS incidence follows a bimodal age pattern. The first window of increased incidence, which accounts for more than 50% of cases, occurs in the first decade. This period peaks at a median of 2 years of age and consists mainly of embryonal (E-RMS) or botryoid RMS (B-RMS). The second peak occurs during adolescence and more commonly consists of alveolar RMS (A-RMS).Objectives: - To assess OS, EFS and DFS with a minimum one year follow up from the last patient.To identify the relationships between different demographic variables with OS, EFS and DFS to identify relevant prognostic factors. To detect relationships between survival rates and different modalities of local control (surgery, radiation therapy or both). Patients and methods: This is a retrospective study to evaluate treatment outcome of patients below 18 years of age, newly diagnosed with rhabdomyosarcoma who were treated at pediatric oncology department, National Cancer Institute (NCI), Cairo University, Egypt during the period from January 2012 to December 2016 Results: 54 pediatric patients with RMS with age ranging from 7 months to 17 years (median age 5 years) were studied. The median follow up period ranged with a median of one year for the last patient
UR  - http://172.23.153.220/th.pdf
ER  -